BioSpace News Archive

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at the scientific conference Bayes@Lund 2024 on March 7, 2024.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches with seed finance from Pureos Bioventures and ND Capital.

Nicox SA, an international ophthalmology company, announced its Board of Directors has appointed the highly experienced biotech executive Gavin Spencer as Chief Executive Officer.

Nicox SA, an international ophthalmology company, announced that it has signed an agreement in principle to amend its debt agreements with funds and accounts managed by BlackRock, Inc. and its affiliates.

Novotech has released an industry-leading report on Duchenne Muscular Dystrophy Clinical Trial Landscape.

ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced that the U.S. Food and Drug Administration cleared the Company to initiate the Phase I-IIa ArthemiR™ study of ATX-01 for the treatment of Myotonic Dystrophy Type 1.

SPT Labtech and RevoluGen Ltd. announce the successful automation of RevoluGen’s Fire Monkey™ High Molecular Weight DNA extraction chemistry in a bead-based format using SPT Labtech’s firefly® automated liquid handling platform.

Royal Philips, a global leader in health technology, announced a significant milestone as it expands access to virtually helium-free MRI to more patients in more places, with more than 1,000 systems now installed worldwide.

Akeso announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody（cadonilimab）combined with standard treatment as first-line treatment for recurrent/metastatic cervical cancer had been published in the official journal of the American Association for Cancer Research, Clinical Cancer Research, with an impact factor of 11.5.

Baird Medical Devices, Inc. announced that it is accelerating its expansion in the United States through senior hires, key partnerships, and capacity building initiatives to support its business.